Medicines Co. Stock
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0.080% | 1.842% | 6.342% | 26.472% | -7.739% | -16.699% | -39.133% |
| Opko Health Inc. | -0.890% | -24.832% | -11.111% | 6.870% | 2.733% | -36.951% | -62.264% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 0.590% | -1.156% | 4.908% | -10.938% | -12.755% | -34.733% | -25.000% |
Comments
News
Travere Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Travere Therapeutics, Inc.? Here are five stocks we like better.
- Record FILSPARI performance: Travere reported $169.6 million in total second-quarter revenue
Gilead Sciences Q2 Earnings Call Highlights
Key Points
- Interested in Gilead Sciences, Inc.? Here are five stocks we like better.
- Base business sales rose 10% year over year to $7.6 billion, led by HIV, oncology and liver treatments
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in ACADIA Pharmaceuticals Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 17% year over year to $308 million, driven by DAYBUE sales of $125 million